Urteste publishes first peer-reviewed paper on Panuri pancreatic cancer test

Urteste said July 22 that a peer-reviewed study in Diagnostics validates the analytical performance of Panuri, its urine-based pancreatic cancer test. The milestone comes as the Poland-based biotech runs a multicenter European clinical study and prepares to present the program at ADLM 2026 in Anaheim.

Why it matters: - The publication gives Urteste peer-reviewed support for the analytical work behind Panuri, a urine-based test for pancreatic cancer. - Panuri is still investigational and has not received CE marking, so the paper does not mean the product is cleared for clinical use. - The study could help Urteste advance European regulatory review under the IVDR and support future commercialization discussions.

What happened: - Urteste said July 22, 2026, that the first peer-reviewed scientific article on Panuri has been published in Diagnostics. - The paper is titled "Development and Analytical Evaluation of Urine-Based Test for Detection of Pancreatic Cancer." - Urteste S.A. is based in Gdansk, Poland, and trades on the Warsaw Stock Exchange under the ticker URT. - The company said the article describes the analytical validation of Panuri, which is designed to detect pancreatic ductal adenocarcinoma, or PDAC. - Urteste said the publication is an important milestone for the company.

The details: - Panuri is an investigational in vitro diagnostic device. - The test uses proprietary synthetic peptides to measure disease-associated proteolytic activity in urine. - Urteste said the analytical development of the Panuri assay showed 89% analytical sensitivity and 75% analytical specificity. - Urteste said precision results were strong, with repeatability, within-laboratory precision and inter-laboratory reproducibility all showing coefficients of variation below 10%. - The published article provides the scientific description of those results and the analytical validation work completed during development. - The article is available in Diagnostics through this journal article. - Urteste is running a prospective multicenter clinical performance study in patients being worked up for suspected pancreatic cancer. - The study is being conducted at 30 sites in Poland, Italy and Hungary. - The study is expected to include about 550 evaluable participants. - The results are intended to support the European regulatory process for Panuri under the IVDR. - Urteste said the company has 13 prototypes of diagnostic tests covering cancers of the breast, brain, stomach, bile ducts, ovaries, bladder, endometrium, kidneys, colon, lungs, liver, pancreas and prostate. - Urteste said those cancers account for nearly 70% of cancer-related deaths worldwide. - Urteste’s technology is based on measuring enzyme activity in urine and using the resulting color change as a cancer signal.

Between the lines: - The peer-reviewed paper gives Urteste a more formal scientific foundation as the company moves from analytical development into clinical validation. - The timing suggests Urteste is trying to build visibility with regulators, partners and investors while the Panuri study is still underway. - CEO Grzegorz Stefański said the company is continuing its international clinical study and plans to share progress at ADLM 2026 in Anaheim.

What's next: - Urteste plans to present the Panuri program at the Association for Diagnostics & Laboratory Medicine 2026 Annual Scientific Meeting & Clinical Lab Expo in Anaheim, California, from July 26–30, 2026. - The company said management board members will attend the event as part of business development efforts. - Urteste plans to discuss the publication, the ongoing clinical study and potential strategic and commercial partnerships at the meeting. - The clinical study will continue across the 30 European sites as Urteste works toward regulatory steps for Panuri.